HOOKIPA doses first patient in HB-201 Phase 1/2 trial for HPV16+ cancers
Category: #headlines  By Saipriya Iyer  Date: 2019-12-31
  • share
  • Twitter
  • Facebook
  • LinkedIn
HOOKIPA doses first patient in HB-201 Phase 1/2 trial for HPV16+ cancers

 

  • HB-201 is an immunotherapy to treat Human Papillomavirus 16-positive (HPV16+) cancers
  • HPV has been estimated to cause nearly 5% of cancers worldwide, majorly due to HPV serotype 16

HOOKIPA Pharma Inc.,  a developer of immunotherapeutics that target cancers and other infectious diseases based primarily on its proprietary arenavirus platform, recently announced that dosing for the first patient was completed in HB-201’s Phase 1/2 clinical trial (NCT04180215).

HB-201 is an immunotherapy to treat Human Papillomavirus 16-positive (HPV16+) cancers. It will be the first clinical trial in immuno-oncology for HOOKIPA.

Apparently, HB-201 is essentially a TheraT platform-based vector that comes from the arenavirus family while expressing a highly antigenic and a non-oncogenic E6/E7 fusion protein from the HPV16. HB-201, under the preclinical studies, had been observed to be extremely immunogenic which would result in a sturdy CD8+T cell response in comparison to the levels that were induced by other approaches, which include adoptive cell therapies. 

HOOKIPA also observed a strong anti-tumor activity in the mouse models besides exhibiting a strong immunogenicity. The company firmly believes that HB-201 has the potential to help provide a therapeutic advantage to patients in the HPV16+ cancer setting.

HOOKIPA’s Chief Executive Officer, Joern Aldag stated that the company is looking forward to starting the first-in-human testing with the help of HB-201, its first clinical trial in immune-oncology. The translation of promising preclinical data for all cancer patients will be an important milestone for the company.  

Aldag further added that the approach of the company is capable of supercharging the natural defense mechanisms by having induced sturdy T cell responses for the benefit of the patients who are affected by infectious diseases and cancer.

THE HB-201 Phase 1/2 trial is basically an open-label dose-escalation as well as a dose-expansion trial to be done in 100 patients suffering from treatment-refractory HPV16+ cancers. It has been designed for the evaluation of tolerability and safety as well as preliminary efficacy of the HB-201 as a monotherapy and for combination therapy with an immune checkpoint inhibitor.

 

Source credit- https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-announces-first-patient-dosed-phase-12-clinical-trial-hb

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

Atos takes quantum simulator to the next level with Atos QLM E
Atos takes quantum simulator to the next level with Atos QLM E
By Saipriya Iyer

Atos, one of the leading companies in digital transformation, has reportedly expanded its quantum solutions portfolio by offering Atos QLM E (Atos QLM Enhanced), the world’s best performing commercially available quantum simulator, with a new r...

Services Australia procures 35,000 monitors & laptops over two months
Services Australia procures 35,000 monitors & laptops over two months
By Saipriya Iyer

Canberra based government department, Services Australia, has been reported to purchase around 20,000 laptops and more than 15,000 monitors over the period of last two months. The purchases have been made owing to the shift in working environment fro...

Twitter introduces Stories-like “Fleets” feature for Indian users
Twitter introduces Stories-like “Fleets” feature for Indian users
By Saipriya Iyer

American microblogging and social networking platform, Twitter, has reportedly announced the launch of its much-anticipated “Fleets” feature for its users in India. Using this feature, people will be able to share photos, tweets, and vide...